EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aytu BioScience Inc (AYTU) fair value: what the stock is really worth

We calculate from audited financials what Aytu BioScience Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US0547548745

AB Aytu BioScience Inc logo Thin data Jul 24, 2026

Aytu BioScience Inc

AYTU · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $1.00 · Strongly overvalued (−56%)
!Quality 25/100
!Weak Growth (revenue 5y +19.2 %/yr)
!Loss-making · -60.2% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Aytu BioScience Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$113.00 $1.00 Fair Value $1.00 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

60‑month range $1.00 – $113.00 · fair‑value band $0.7480 – $1.51 · the $2.28 price screens above the $1.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.

Follow Aytu BioScience in your weekly email

Every Wednesday you see whether Aytu BioScience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.

Show more

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Stock analysis

Aytu BioScience Inc (AYTU) currently trades at $2.28, while our model-based Fair Value estimate is $1.00, implying the stock looks roughly 127.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.7480 (bear) to $1.51 (bull), the price of $2.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Aytu BioScience Inc reported revenue of $66.4M in FY2025 versus $65.6M in FY2021, a compound +0.3%/yr. Reported net income was −$13.6M in FY2025.

Key figures

Market cap $22.6M · P/S ratio 0.40 · EPS (TTM) $−4.61 · Net margin −20.4% · Return on equity −97.4% · Return on assets (EBIT) −24.4% · Operating margin −32.7% · Revenue (TTM) $56.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 21% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −56%, AYTU screens richer than that median.

Fair Value models

Bear $0.7480 Fair Value $1.00 Bull $1.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.8800 $1.18 $1.77 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.8800 $1.18 $1.77 54

Open the full fair value analysis →

Notify me when AYTU reaches fair value

Put AYTU on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 26 · Market factors (momentum, volatility) 41

Profitability 20
Margins and returns on capital today
Quality Growth 28
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 34
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 34
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Start year 2020 (pandemic). Over 10 years: +73.9% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+93.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−76.5% (2020) → −11.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AYTU screens 127% overvalued. Compare with Merck KGaA →

Compare Aytu BioScience Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −56% · Bottom 25%
Profitability
Return on assets −4% · Bottom 25%
Net margin (TTM) −60% · Bottom 25%
Operating margin (TTM) −33% · Bottom 25%
Growth and dividend
Revenue growth −33% · Bottom 25%
Balance sheet
Debt / equity 0.57× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.19× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.40× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)0 · sector 27
HEALTH (low debt)71 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aytu BioScience Inc · Fair Value
$1.00 −127%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aytu BioScience Inc Fair Value". https://www.fairvalue-calculator.com/stock/AYTU

Frequently asked questions

Is Aytu BioScience Inc (AYTU) overvalued or undervalued?
As of Jul 24, 2026, our model estimates a fair value of $1.00 versus a price of $2.28, about −56% upside (overvalued).
What is the fair value of AYTU?
Our model-based fair value for Aytu BioScience Inc is $1.00 (as of Jul 24, 2026), built from audited fundamentals. The current price: $2.28.
What is the quality score of AYTU?
Aytu BioScience Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aytu BioScience Inc (AYTU)?
Our model-based price target is the fair value of $1.00 (as of Jul 24, 2026) from 1 valuation models. Cautious scenario $0.7480, optimistic scenario $1.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Aytu BioScience Inc stock forecast for 2026?
Our models put fair value at $1.00, about −56% upside versus a price of $2.28 (overvalued). Cautious scenario $0.7480, optimistic scenario $1.51. The calculation is refreshed regularly with new filings.
What is the revenue of Aytu BioScience Inc (AYTU)?
Aytu BioScience Inc reported trailing-twelve-month revenue of about $56.6M (latest available figure, as of Jul 24, 2026).
What is the intrinsic value of Aytu BioScience Inc (AYTU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aytu BioScience Inc it is $1.00 per share (as of Jul 24, 2026), against a price of $2.28. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aytu BioScience Inc stock overvalued or undervalued in 2026?
As of Jul 24, 2026, AYTU trades above its calculated fair value: price $2.28, fair value $1.00, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AYTU?
No. The price is what the market pays today ($2.28); the fair value is what the company's own numbers justify ($1.00). For Aytu BioScience Inc the two are $1.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aytu BioScience Inc worth?
The market values Aytu BioScience Inc at about $22.6M (market capitalisation, as of Jul 24, 2026). Per share that is $2.28; our models calculate a fair value of $1.00 per share.
What do the bullish and bearish scenarios say about AYTU?
Our models span a range for Aytu BioScience Inc: cautious scenario $0.7480, base $1.00, optimistic $1.51 per share (as of Jul 24, 2026, price $2.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aytu BioScience Inc (AYTU)?
Balance-sheet figures for Aytu BioScience Inc (as of Jul 24, 2026): return on equity −97.4%, debt of 0.57 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is AYTU from its 52-week high?
Aytu BioScience Inc trades at $2.28, about 21% below its 52-week high of $2.90 and 33% above the low of $1.71 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.00 is for.
Which stocks are comparable to Aytu BioScience Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aytu BioScience Inc stock attractive at the current price?
The data as of Jul 24, 2026: price $2.28, calculated fair value $1.00 (−56%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AYTU calculated?
We run Aytu BioScience Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Aytu BioScience Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aytu BioScience Inc (AYTU)?
The closing price on Sep 23, 2026 was $2.28. Our model-based fair value is $1.00, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aytu BioScience Inc right now?
The price sits above even our optimistic bull case ($1.51). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.7480 to $1.51) leaves room in how you read the outcome.

Key figures of Aytu BioScience Inc

How large is the market capitalisation of Aytu BioScience Inc (AYTU)?
The market capitalisation of Aytu BioScience Inc is $22.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aytu BioScience Inc (AYTU)?
The price-to-sales ratio of Aytu BioScience Inc is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aytu BioScience Inc (AYTU)?
Earnings per share at Aytu BioScience Inc are $−4.61. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aytu BioScience Inc (AYTU)?
The net margin of Aytu BioScience Inc is −20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aytu BioScience Inc (AYTU)?
The return on equity (ROE) of Aytu BioScience Inc is −97.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aytu BioScience Inc (AYTU)?
On an EBIT basis the return on assets of Aytu BioScience Inc is −24.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aytu BioScience Inc (AYTU)?
The operating margin of Aytu BioScience Inc is −32.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aytu BioScience Inc (AYTU)?
Revenue at Aytu BioScience Inc is growing −32.7% versus a year earlier (3y avg −11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aytu BioScience Inc (AYTU) generate?
The free cash flow of Aytu BioScience Inc is −$5.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aytu BioScience Inc (AYTU) hold?
Aytu BioScience Inc holds more cash than debt, $8.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Aytu BioScience Inc in the live analysis

One click puts Aytu BioScience Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.